Abstract
Background With treatment trials on the horizon, this study aimed to identify candidate digital-motor gait outcomes for Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS), capturable by wearable sensors with multi-center validity, and ideally also ecological validity during free walking outside laboratory settings.
Methods Cross-sectional multi-center study (4 centers), with gait assessments in 36 subjects (18 ARSACS patients; 18 controls) using three body-worn sensors (Opal, APDM) in laboratory settings and free walking in public space. Sensor gait measures were analyzed for discriminative validity from controls, and for convergent (i.e. clinical and patient-relevance) validity by correlations with SPRSmobility (primary outcome) and SARA, SPRS and FARS-ADL (exploratory outcomes).
Results Of 30 hypothesis-based digital gait measures, 14 measures discriminated ARSACS patients from controls with large effect sizes (|Cliff’s δ| > 0.8) in laboratory settings, with strongest discrimination by measures of spatiotemporal variability Lateral Step Deviation (δ=0.98), SPcmp (δ=0.94) and Swing CV (δ=0.93). Large correlations with the SPRSmobility were observed for Swing CV (Spearman’s ρ = 0.84), Speed (ρ=-0.63) and Harmonic Ratio V (ρ=-0.62). During supervised free walking in public space, 11/30 gait measures discriminated ARSACS from controls with large effect sizes. Large correlations with SPRSmobility were here observed for Swing CV (ρ=0.78) and Speed (ρ=-0.69), without reductions in effect sizes compared to lab settings.
Conclusion We identified a promising set of digital-motor candidate gait outcomes for ARSACS, applicable in multi-center settings, correlating with patient-relevant health aspects, and with high validity also outside lab settings, thus simulating real-life walking with higher ecological validity.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the DFG under the frame of EJP-RD network PROSPAX (No 441409627; to M.S., R.S, F.S., C.G., A.N.B) and by the Clinician Scientist program "PRECISE.net" funded by the Else Kroener-Fresenius-Stiftung (to L.B., A.T., and M.S.). A.T. received funding from University of Tuebingen, medical faculty, for the Clinician Scientist Program Grant #439-0-0. F.M.S. is supported in part by the Italian Ministry of Health (the EJP-RD network PROSPAX; Ricerca Finalizzata RF-2019-12370417; Ricerca Corrente 2023, RC 5x1000).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of the University of Tuebingen gave ethical approval for this work (AZ 824/2019BO2)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* shared last authors
Data availability statement
Data will be made available upon reasonable request and as patient consent allows.